

EUR Research Information Portal

Mycoplasma pneumoniae

Published in:

The Lancet Microbe

Publication status and date:

Published: 01/10/2023

DOI (link to publisher):

[10.1016/S2666-5247\(23\)00182-9](https://doi.org/10.1016/S2666-5247(23)00182-9)

Document Version

Publisher's PDF, also known as Version of record

Document License/Available under:

CC BY-NC-ND

Citation for the published version (APA):

Meyer Sauter, P. M., & ESGMAC the ESGMAC MAPS study group (2023). Mycoplasma pneumoniae: gone forever? *The Lancet Microbe*, 4(10), e763. [https://doi.org/10.1016/S2666-5247\(23\)00182-9](https://doi.org/10.1016/S2666-5247(23)00182-9)

[Link to publication on the EUR Research Information Portal](#)

Terms and Conditions of Use

Except as permitted by the applicable copyright law, you may not reproduce or make this material available to any third party without the prior written permission from the copyright holder(s). Copyright law allows the following uses of this material without prior permission:

- you may download, save and print a copy of this material for your personal use only;
- you may share the EUR portal link to this material.

In case the material is published with an open access license (e.g. a Creative Commons (CC) license), other uses may be allowed. Please check the terms and conditions of the specific license.

Take-down policy

If you believe that this material infringes your copyright and/or any other intellectual property rights, you may request its removal by contacting us at the following email address: openaccess.library@eur.nl. Please provide us with all the relevant information, including the reasons why you believe any of your rights have been infringed. In case of a legitimate complaint, we will make the material inaccessible and/or remove it from the website.

THE LANCET Microbe

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Sauteur PMM, Beeton ML. *Mycoplasma pneumoniae*: gone forever? *Lancet Microbe* 2023; published online June 29. [https://doi.org/10.1016/S2666-5247\(23\)00182-9](https://doi.org/10.1016/S2666-5247(23)00182-9).

Supplementary appendix

Appendix 1:	ESGMAC MAPS study group members	page 2
Appendix 2:	Supplementary Table S1	page 6
Appendix 3:	Supplementary Table S2	page 10
Appendix 4:	Supplementary Figure S1	page 13
	Contributors	page 14
	References	page 15

ESGMAC MAPS study group members

FRANCE:

Sabine Pereyre¹, Cécile Bébéar¹, Marie Gardette¹, Nadège Hénin¹

¹ *Bacteriology Department, Bordeaux University Hospital, National Reference Center for Bacterial Sexually Transmitted Infections, Bordeaux, France*

SWITZERLAND:

Noémie Wagner¹, Adrien Fischer², Alessandra Vitale³, Julie Kessler³, Corinne Andreutti³, Gilbert Greub⁴, Petra Zimmermann⁵, Philipp K. A. Agyeman⁶, Christoph Aebi⁶, Michael Buettcher⁷, Marisa Hostettler⁷, Lisa Kottanattu⁸, Valeria Gaia⁹, Frank Imkamp¹⁰, Adrian Egli¹⁰, Christoph Berger¹¹, Semjon Sidorov¹¹, Romy Tilen¹¹, Anita Niederer-Loher¹², Florence Barbey¹³, Ulrich Heininger¹⁴, Branislav Ivan¹⁵

¹ *Pediatric Infectious Diseases Unit, Department of Pediatrics, Gynecology and Obstetrics, Geneva University Hospital, Geneva, Switzerland*

² *Bacteriology Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals, Geneva, Switzerland*

³ *Clinique de La Source - Laboratories, Lausanne, Switzerland*

⁴ *Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland*

⁵ *Department of Pediatrics, Fribourg Hospital, Fribourg, Switzerland*

⁶ *Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland*

⁷ *Pediatric Infectious Diseases, Department of Pediatrics, Lucerne Children's Hospital, Lucerne Cantonal Hospital, Switzerland*

⁸ *Pediatric Infectious Diseases, Pediatric Institute of Southern Switzerland, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland*

⁹ *Institute of Laboratory Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland*

¹⁰ *Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland*

¹¹ *Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland*

¹² *Children's Hospital of Eastern Switzerland, St Gallen, Switzerland*

¹³ *Cantonal Hospital Aarau, Switzerland*

¹⁴ *Department of Infectious Diseases and Vaccinology, University of Basel Children's Hospital (UKBB), Switzerland*

¹⁵ *Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland*

GERMANY:

Cihan Papan¹, Sören L. Becker², Johannes Forster³, Colin R. MacKenzie⁴, Birgit Henrich⁴, Malte Kohns Vasconcelos⁴

¹ *Institute for Hygiene and Public Health, University Hospital Bonn, Bonn, Germany*

² *Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany*

³ *Institute for Hygiene and Microbiology, University of Würzburg, Würzburg, Germany*

⁴ *Institute of Medical Microbiology and Hospital Hygiene, Heinrich-Heine University Hospital, Düsseldorf, Germany*

BELGIUM:

Melissa Vermeulen¹, Nathalie Bossuyt¹, Veerle Matheeußen²

¹ *Belgian Sentinel Network of Laboratories (SNL), coordinated by the national public health institute Sciensano, Brussels, Belgium*

² *Department of Microbiology, Belgian National Reference Centre for Respiratory Pathogens, Antwerp University Hospital, Edegem, Belgium*

THE NETHERLANDS:

Mireille van Westreenen¹, Nelianne J. Verkaik¹, Marius Vogel¹, Annemarie M.C. van Rossum^{1,2}

¹ *Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands*

² *Department of Pediatrics, Division of Infectious Diseases and Immunology, Erasmus MC University Medical Center–Sophia Children’s Hospital, Rotterdam, The Netherlands*

ENGLAND:

Baharak Afshar¹

¹ *Respiratory and Vaccine Preventable Bacteria Reference Unit (RVPBRU), UK Health Security Agency (UKHSA), London, United Kingdom*

DENMARK:

Søren Anker Uldum¹, Hanne-Dorthe Emborg²

¹ *Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark*

² *Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark*

SWEDEN:

Karolina Gullsby¹

¹ *Center for Research and Development, Uppsala University/Region Gävleborg, Gävle, Sweden*

FINLAND:

Miia Laine¹, Ville Peltola², Santtu Heinonen³

¹ *Department of Clinical Microbiology, Turku University Hospital, Turku, Finland, and Institute of Biomedicine, University of Turku, Turku, Finland*

² *Department of Pediatrics and Adolescent Medicine, University of Turku, Turku, Finland*

³ *New Children’s Hospital, Pediatric Research Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland*

NORWAY:

Henrik Døllner¹, Frode Gran Width², Andreas Christensen²

¹ *Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Children’s Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway*

² *Department of Medical Microbiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway*

ITALY:

Danilo Buonsenso¹

¹ *Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy*

PORTUGAL:

Fernanda Maria Pereira Rodrigues¹, Jorge Rodrigues²

¹ *Emergency Service and Infectiology Unit, Pediatric Hospital, Coimbra Hospital and University Center, Coimbra, Portugal*

² *Department of Pediatrics, Centro Hospitalar Tondela-Viseu, Viseu, Portugal*

GREECE:

Katerina Tsantila¹, Minos Matsas¹, Eleni Kalogera², Evangelia Petridou², Ioannis Kopsidas³

¹ *Department of Microbiology & Serology, P. & A. Kyriakou Children's Hospital, Athens, Greece*

² *Microbiology Department, "Agia Sofia" Children's Hospital, Athens, Greece*

³ *Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, Greece*

SLOVENIA:

Darja Keše¹

¹ *Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia*

ISRAEL:

Ran Nir-Paz¹, Hila Elinav¹, Ayelet Michael-Gayego¹

¹ *Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel*

JAPAN:

Tomohiro Oishi¹, Takeshi Saraya²

¹ *Department of Clinical Infectious Diseases, Kawasaki Medical School, Kurashiki, Japan*

² *Department of Respiratory Medicine, Kyorin University School of Medicine, Mitaka City, Tokyo, Japan*

TAIWAN:

Yu-Chia Hsieh¹, Tsung Hua Wu²

¹ *Department of Pediatrics, Chang Gung Children's Hospital, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan*

² *Department of Pediatrics, Show Chwan Memorial Hospital, Changhua, Taiwan*

SINGAPORE:

Matthias Maiwald^{1,2,3}, Liat Hui Loo^{1,2}

¹ *Department of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore*

² *Duke-NUS Medical School, Singapore*

³ *Yong Loo Lin School of Medicine, National University of Singapore, Singapore*

INDIA:

Tanu Sagar¹, Rama Chaudhry¹

¹ *Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India*

UNITED STATES OF AMERICA:

Larry K. Kociolek¹

¹ *Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, USA*

CUBA:

Nadia Rodríguez¹

¹ *Center for Research, Diagnosis and Reference, Institute of Tropical Medicine "Pedro Kourí", Havana, Cuba*

AUSTRALIA:

David Lorenz¹

¹ *Division of Microbiology, SydPath St Vincent's Hospital, Sydney, Australia*

NEW ZEALAND:

Matthew R. Blakiston¹

¹ *LabPlus, Auckland City Hospital, Auckland, New Zealand*

Supplementary Table S1. Laboratory information and reporting characteristics of participating sites, by United Nations (UN) region.

UN region and country	City or region	Laboratory and/or system	Test method (technique; product)	Company or reference	Ethical approval for data submission required according to local regulations	De-duplication	Exclusion
Europe							
Western Europe							
- France	Bordeaux	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; in-house)	¹	No**	All the numbers provided are from episodes of patients being tested. This means that if a patient has been tested more than once within 90 days, only the first positive or, when the patient only tested negative, the first negative test has been retained for analysis.	None given
- Switzerland	Geneva	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; BioGX Sample-Ready BD MAX System)	BD Diagnostics	No**	None given	None given
	Lausanne (A)	Hospital / clinical laboratory (secondary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No**	None given	None given
	Lausanne (B)	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; in-house)	²	2020-01300	None given	None given
	Fribourg	Hospital / clinical laboratory (secondary center)	NAAT (PCR, real-time; in-house)	–	No**	None given	None given
	Bern*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; Anyplex II RB5 Detection)	Seegene Inc.	No**	None given	None given
	Lucerne*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No**	None given	None given
	Bellinzona	Hospital / clinical laboratory (regional; 0.4 million population)^a	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel) ^b	bioMérieux/BioFire Diagnostics	No**	None given	None given
	Zurich (A)	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; in-house)	³	No**	None given	None given
	Zurich (B)*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No**	All the numbers provided are from episodes of patients being tested. This means that if a patient has been tested more than once within 90 days, only the first positive or, when the patient only tested negative, the first negative test has been retained for analysis.	None given
	St. Gallen*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; Allplex Respiratory Panel)	Seegene Inc.	No**	None given	None given
	Aarau	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No**	None given	None given
	Basel*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No**	None given	None given
- Germany	Homburg	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; AID CAP Bac PCR Kit)	Autoimmun Diagnostika GmbH (AID)	No**	None given	None given
			<i>CLIA (Mycoplasma pneumoniae LIAISON IgM and IgG)***</i>	<i>DiaSorin S.p.A.</i>			
	Würzburg	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; GeneProof Mycoplasma pneumoniae)	GeneProof	No**	None given	None given
			<i>ELISA (EUROIMMUN Mycoplasma pneumoniae IgM and IgG)***</i>	<i>EUROIMMUN AG</i>			

Supplementary appendix

UN region and country	City or region	Laboratory and/or system	Test method (technique; product)	Company or reference	Ethical approval for data submission required according to local regulations	De-duplication	Exclusion
- Belgium	Düsseldorf	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; in-house)	4	No**	None given	None given
	National surveillance****	Surveillance system (national; 60% of all Belgian microbiology laboratories)^c	Direct test methods (different techniques) ^c	5	No**	All the numbers provided are from episodes of patients being tested. This means that if a patient has been tested more than once within 90 days, only the first positive or, when the patient only tested negative, the first negative test has been retained for analysis.	The data of the SNL include "Mycoplasma-like illness" syndromes cases confirmed by direct detection in nasopharyngeal or oropharyngeal swabs, or lower respiratory tract specimens. Cases based on serology have been excluded. No total test numbers available and/or reported.
- The Netherlands	Antwerp (national reference laboratory)	Hospital / clinical laboratory (tertiary center) and national reference laboratory	NAAT (PCR, real-time; in-house)	6	No**	None given	None given.
	Rotterdam*	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; in-house)	7	No**	None given	None given
Northern Europe							
- England	National reference laboratory	National reference laboratory	NAAT (multiplex PCR, real-time; in-house)	8	No**	Duplicates have been removed in each month.	None given
- Denmark	National surveillance	Surveillance system (national; 5.8 million population)	NAAT (PCR, different techniques) ^d	9	Yes (available)	At individual level only the first mycoplasma positive test result within a season is included. If several negative mycoplasma tests are available per individual, only one negative mycoplasma test is included/counted per week.	The first time an individual test positive for mycoplasma all subsequent negative and positive mycoplasma tests are excluded.
- Sweden	National surveillance	Surveillance system (national; 10.5 million population)^e	NAAT (PCR, different techniques)	–	No**	None given	None given
- Finland	National surveillance****	Surveillance system (national; 5.5 million population)	Combination of direct and indirect test methods (different techniques) ^f	10	No**	None given	No total test numbers available and/or reported.
- Norway	Turku	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; Allplex Respiratory Panel 4)	Seegene Inc.	No**	None given	None given
	Trondheim*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; in-house)	–	No**	None given	None given
Southern Europe							
- Italy	Rome*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No**	None given	None given

Supplementary appendix

UN region and country	City or region	Laboratory and/or system	Test method (technique; product)	Company or reference	Ethical approval for data submission required according to local regulations	De-duplication	Exclusion
- Portugal	Coimbra*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	Yes (available)	None given	None given
	Viseu*	Hospital / clinical laboratory (secondary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	Yes (available)	None given	None given
- Greece	Athens (A)*	Hospital / clinical laboratory (tertiary center)	ELISA (Serion ELISA Classic Mycoplasma pneumoniae IgM and IgG)	Virion\Serion, Würzburg, Germany	No**	None given	None given
	Athens (B)*	Hospital / clinical laboratory (tertiary center)	ELISA (NovaLisa Mycoplasma pneumoniae IgM and IgG)	Novatec Immun-diagnostics GmbH	No**	None given	None given
- Slovenia	Ljubljana	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; Chla/Myco pneumo R-GENE)	bioMérieux/ARGENE	Yes (0120-244/2021/3)	Duplicate samples from the same patients were included as a single case.	None given
Asia							
Western Asia							
- Israel	Jerusalem	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; in-house)	8	Yes (HMO 460-12)	None given	None given
Eastern Asia							
- Japan	Kurashiki City (Okayama)*	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; in-house)	11	Yes (3119-1)	None given	None given
	Mitaka City (Tokyo)	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; in-house)	–	Yes (available)	None given	None given
- Taiwan	Taoyuan*	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; in-house)	12	Yes (201900420A3C502)	None given	None given
	Changhua City*	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; in-house)	13	Yes (1051007)	None given	None given
South-eastern Asia							
- Singapore	Singapore*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No**	None given	None given
South Asia							
- India	New Delhi	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, real-time; in-house) ELISA (NovaLisa Mycoplasma pneumoniae IgM)***	Novatec Immun-diagnostics GmbH	–	Yes (available)	None given
America							
Northern America							
- United States of America (USA)	Chicago*	Hospital / clinical laboratory (tertiary center)	NAAT (multiplex PCR, microarray; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	Yes (available)	None given	None given
Caribbean							
- Cuba	National surveillance	Surveillance system (national; 11.3 million population)	NAAT (PCR, real-time; in-house)	14	Yes (1901074)	None given	None given
Oceania							
- Australia	Darlinghurst (Sydney)	Hospital / clinical laboratory (tertiary center)	NAAT (PCR, real-time; EasyScreen Respiratory Pathogen Detection Kit)	Genetic Signatures	Yes (available)	None given	None given
			CLIA (Mycoplasma pneumoniae LIAISON IgM and IgG)***	Biotrin International Ltd.			
- New Zealand	Auckland	Hospital / clinical laboratory (tertiary center)	NAAT (in-house multiplex PCR; FilmArray Respiratory Panel)	bioMérieux/BioFire Diagnostics	No**	None given	None given

Abbreviations: CLIA, chemiluminescent immunoassay; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin; NAAT, nucleic acid amplification test; PCR, polymerase chain reaction.

Supplementary appendix

* $\geq 90\%$ of data are from children and adolescents < 18 years of age.

** Survey participants confirmed that ethical review and approval is not required for aggregated and anonymized data according to local regulations.

*** In addition to PCR also serological data separately reported for the same site.

**** Exclusively positive test numbers (and no total test numbers) available and/or reported.

National and/or regional surveillances or reference laboratories are indicated in bold.

Serology is indicated in italic and with gray background.

^a Data from several hospitals in the region of Ticino.

^b Additional use of a specific in-house PCR.⁶

^c Data collected through the Belgian Sentinel Network of Laboratories (SNL), a network of approximately 95 microbiology laboratories (i.e., 60% of all Belgian microbiology laboratories)⁵, based on direct test methods such as NAAT, antigen test, culture, microscopy, "unknown", or "other" (cases based on serology were excluded).

^d Different PCR assays, of which some are published⁹ or commercial kits, but most are unpublished but validated in-house assays.

^e No national surveillance program for *M. pneumoniae*, but data collected nationwide for this study (from approximately 75% of the laboratories, with an uptake of around 75% of the population in Sweden).

^f No distinction possible between detection methods, but predominantly serology (about 75%; no information on isotypes), partly multiplex PCR (Allplex Respiratory Panel, Seegene Inc.; about 25%).

Supplementary Table S2. *M. pneumoniae* testing and detection rates from April 2022–March 2023.

UN region and country	City or region	Test method	Positive tests (n)													Total	Total tests (n)													
			2022												2023		2022												2023	Total
			Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr		May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar			
Europe																														
Western Europe																														
- France	Bordeaux	PCR	0	0	0	0	0	0	0	0	0	0	2	0	2	4	44	31	36	39	27	30	47	28	42	49	47	56	476	
- Switzerland	Geneva	PCR	0	0	0	0	0	0	0	2	1	2	NA	NA	5	139	131	113	121	101	117	150	176	257	207	NA	NA	1512		
	Lausanne (A)	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	84	44	55	56	53	48	72	106	180	176	116	97	1087		
	Lausanne (B)	PCR	0	0	1	0	0	0	0	2	0	1	2	1	7	97	87	111	96	67	85	106	116	98	98	93	101	1155		
	Fribourg	PCR	0	NA	0	0	0	0	0	0	0	0	NA	NA	0	1	0	1	5	1	1	5	1	2	2	0	NA	19		
	Bern*	PCR	0	0	0	1	0	0	0	0	0	0	0	0	1	12	14	9	9	21	13	17	17	14	12	12	9	159		
	Lucerne*	PCR	0	0	0	0	0	0	0	1	0	0	0	0	1	43	43	36	48	30	37	39	50	51	46	38	43	504		
	Bellinzona	PCR	0	0	0	0	0	0	1	1	0	3	0	1	6	152	145	141	90	128	137	197	276	338	218	235	209	2266		
	Zurich (A)	PCR	0	1	0	0	0	0	0	0	0	0	0	0	1	140	184	168	141	187	162	155	155	150	133	143	133	1851		
	Zurich (B)*	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	87	65	65	56	61	62	58	95	107	103	113	115	987		
	St. Gallen*	PCR	0	0	0	NA	NA	0	0	0	NA	NA	NA	0	0	1	1	1	1	0	2	1	3	0	0	1	10			
	Aarau	PCR	0	0	0	0	0	0	1	1	0	2	1	1	6	82	92	80	63	60	77	63	105	129	126	101	109	1087		
		IgM ELISA	0	0	0	3	0	0	0	0	1	0	0	0	4	7	7	4	6	2	7	10	10	6	4	9	5	77		
		IgG ELISA	3	1	1	2	1	3	3	5	3	2	2	1	27	7	7	4	6	2	7	10	10	6	4	9	5	77		
	Basel*	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	112	141	132	82	100	151	158	218	169	106	132	101	1602		
- Germany	Homburg	PCR	0	0	0	1	0	0	0	0	0	0	0	0	1	197	166	142	184	206	208	165	180	186	170	175	216	2195		
		IgM ELISA	1	0	4	3	2	5	1	1	4	3	2	8	34	4	38	42	55	56	41	43	39	51	29	36	64	498		
		IgG ELISA	0	8	1	6	4	1	8	3	4	1	0	6	42	4	38	42	55	56	41	43	39	51	29	36	64	498		
	Würzburg	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	69	75	96	97	60	79	15	85	46	63	4	91	780		
		IgM ELISA	0	0	0	1	1	0	1	3	1	1	1	0	9	19	16	6	11	11	11	11	11	10	16	13	5	140		
		IgG ELISA	6	6	3	9	8	5	6	5	5	8	8	3	72	19	16	6	11	11	11	11	11	10	16	13	5	140		
	Düsseldorf	PCR	0	2	4	0	0	0	3	0	0	0	0	0	9	93	85	85	90	88	78	83	89	101	112	114	121	1139		
		IgM ELISA	2	3	4	4	5	5	2	2	4	8	8	4	51	15	20	29	20	29	14	32	25	19	33	13	20	269		
		IgG ELISA	7	6	14	7	18	11	18	10	13	16	8	8	136	15	20	29	20	29	14	32	25	19	33	13	20	269		
- Belgium	National surveillance**	Direct test methods (different techniques) ^a	16	15	10	8	10	21	15	27	25	16	11	20	194	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
	Antwerp	PCR	0	0	0	0	0	0	0	0	0	0	1	1	2	77	65	72	77	46	63	72	106	132	109	74	77	970		
- The Netherlands	Rotterdam*	PCR	0	0	0	1	1	0	0	0	0	0	0	0	2	32	12	26	16	16	18	12	8	24	25	32	11	232		
		IgM ELISA	0	0	1	0	2	2	0	3	3	0	3	2	16	9	8	10	7	4	13	9	11	19	14	9	14	127		
		IgG ELISA	1	3	1	0	1	1	0	1	2	1	1	6	18	9	8	10	7	4	19	9	11	19	14	9	14	133		
Northern Europe																														
- England	National reference laboratory	PCR	0	0	0	0	0	0	0	0	0	1	1	2	9	11	14	5	10	15	11	14	11	7	9	15	131			

Supplementary appendix

UN region and country	City or region	Test method	Positive tests (n)													Total tests (n)														
			2022			2023										Total	2022			2023										Total
			Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar	Apr		May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar			
- Denmark	National surveillance	PCR	1	0	0	1	5	6	5	9	9	20	16	17	89	7455	7013	6948	5672	5709	6052	8037	9155	10756	10908	9251	9746	96702		
- Sweden	National surveillance	PCR	0	0	3	0	0	1	0	2	3	1	3	4	17	2195	2333	2460	2244	2245	2456	2526	2839	3688	2942	2121	2339	30388		
- Finland	National surveillance**	Serology or PCR ^b	39	26	32	21	29	35	24	20	30	33	26	33	348	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		
	Turku	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	48	55	52	47	57	55	81	63	65	62	49	66	700		
		IgM ELISA	1	4	1	4	4	4	3	1	2	4	5	3	36	114	162	107	113	171	189	164	205	157	163	131	183	1859		
		IgG ELISA ^c	0	0	0	0	0	1	0	0	0	0	0	0	1	114	161	107	111	169	186	163	205	157	161	131	180	1845		
- Norway	Trondheim*	PCR	0	0	0	0	0	0	1	0	0	0	0	0	1	120	166	145	116	97	130	125	173	239	182	149	162	1804		
Southern Europe																														
- Italy	Rome*	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	NA	NA	NA	30	57	113	45	87	32	3	2	5	374		
- Portugal	Coimbra*	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	281	263	185	225	293	263	374	320	309	225	182	176	3096		
	Viseu*	PCR	0	0	0	0	0	1	0	1	0	0	0	0	2	8	12	10	12	4	11	21	30	28	32	36	44	248		
		IgM ELISA	0	0	0	0	0	2	1	2	1	0	0	0	4	0	2	1	2	0	2	3	4	9	3	2	0	28		
		IgG ELISA	0	2	0	0	0	1	0	0	2	0	1	0	6	0	2	1	2	0	2	3	4	9	3	2	0	28		
- Greece	Athens (A)*	IgM ELISA	7	2	5	4	5	5	5	14	7	6	3	13	76	21	22	14	17	25	20	26	25	26	22	22	34	274		
		IgG ELISA	4	2	2	4	8	5	2	5	5	3	2	4	46	21	22	14	17	25	20	26	25	26	22	22	34	274		
	Athens (B)*	IgM ELISA	0	2	2	3	2	0	1	2	2	1	2	0	17	14	18	14	29	19	11	30	29	18	22	25	30	259		
		IgG ELISA	9	9	8	12	11	3	12	14	11	16	13	15	133	14	18	14	29	19	11	30	29	18	22	25	30	259		
- Slovenia	Ljubljana	PCR	0	0	0	0	0	0	0	1	2	2	0	0	5	104	122	123	97	121	135	131	162	164	155	104	140	1558		
Asia																														
Western Asia																														
- Israel	Jerusalem	PCR	0	0	0	0	0	0	0	0	0	0	2	1	3	92	115	83	76	81	84	83	142	125	124	126	163	1294		
Eastern Asia																														
- Japan	Kurashiki City (Okayama)*	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	3	5	11	14	17	22	11	41	15	8	14	9	170		
	Mitaka City (Tokyo)	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	8	8	13	7	10	9	15	17	15	29	19	17	167		
- Taiwan	Taoyuan*	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	85	82	83	79	96	94	120	143	129	126	177	127	1341		
	Changhua City	PCR	8	0	0	0	2	3	0	0	0	0	0	5	18	21	6	4	4	10	23	25	25	9	5	10	22	164		
South-eastern Asia																														
- Singapore	Singapore*	PCR	0	0	0	0	0	0	1	0	2	3	6	4	16	1535	1991	2191	2404	2064	2143	2511	2147	1947	2168	2303	2770	26174		
South Asia																														
- India	New Delhi	PCR	4	2	1	4	2	0	0	0	0	0	1	0	14	12	13	6	11	12	9	8	20	2	11	9	9	122		
		IgM ELISA	0	2	1	1	1	1	0	3	0	3	0	0	12	12	13	6	11	12	9	8	20	2	11	9	9	122		

Supplementary appendix

UN region and country	City or region	Test method	Positive tests (n)													Total tests (n)																									
			2022			2023										Total	2022			2023										Total											
			Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar		Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Jan	Feb	Mar														
America																																									
Northern America																																									
- USA	Chicago*	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	561	681	634	612	581	772	848	871	735	552	800	803	8450
Caribbean																																									
- Cuba	National surveillance	PCR	0	0	0	0	1	NA	1	0	0	0	0	0	NA														31	50	72	21	69	0	36	39	1	33	1	0	353
Oceania																																									
- Australia	Darlinghurst (Sydney)	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	854	1390	1685	1736	1416	1183	988	1402	1232	957	756	1178	14777
		<i>IgM ELISA</i>	8	3	7	5	4	4	2	1	2	4	5	2															46	64	56	69	50	69	67	50	49	48	42	31	641
		<i>IgG ELISA</i>	7	6	9	10	7	12	12	7	11	4	5	3															46	64	56	69	50	69	67	50	49	48	42	31	641
- New Zealand	Auckland	PCR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	403	459	602	489	520	623	623	618	457	490	389	490	6163

Abbreviations: ELISA, enzyme-linked immunosorbent assay; Ig, immunoglobulin; PCR, polymerase chain reaction.

* ≥90% of data are from children and adolescents <18 years of age.

** Exclusively positive test numbers (and no total test numbers) available and/or reported.


Serological data (± PCR) are indicated in italic and with gray background.

^a Data based on direct test methods such as PCR, antigen test, culture, microscopy, "unknown", or "other" (cases based on serology were excluded).

^b No distinction possible between detection methods, but predominantly serology.

^c Positive results based on IgG testing from paired serum specimens.

Supplementary Figure S1. *Mycoplasma pneumoniae* detections by PCR across the world from April 1, 2022 to March 31, 2023, the 3rd year after the worldwide introduction of NPIs against COVID-19 in March 2020. **(A)** Bar of pie chart with number and proportion of positive and negative PCR test results (pie chart) and detections separated by country (bar). **(B)** Stacked area chart with number of detections per month and year for each country. The two national surveillances with only positive test numbers available (and no total test numbers) are not included (Belgium and Finland, appendix 3).



Contributors

PMMS and MLB designed, initiated, and coordinated the study. All authors and the ESGMAC MAPS study group members supplied *M. pneumoniae* detection numbers. PMMS analysed and interpreted the data with support by MLB. PMMS wrote a first draft of the paper. MLB read, commented on, and approved the final manuscript. All authors had full access to and verified all the data in the study and had final responsibility for the decision to submit for publication.

References

- 1 Touati A, Benard A, Hassen AB, Bébéar CM, Pereyre S. Evaluation of five commercial real-time PCR assays for detection of *Mycoplasma pneumoniae* in respiratory tract specimens. *J Clin Microbiol* 2009; **47**: 2269-71.
- 2 Welti M, Jatón K, Altwegg M, Sahli R, Wenger A, Bille J. Development of a multiplex real-time quantitative PCR assay to detect *Chlamydia pneumoniae*, *Legionella pneumophila* and *Mycoplasma pneumoniae* in respiratory tract secretions. *Diagn Microbiol Infect Dis* 2003; **45**: 85-95.
- 3 Meyer Sauter PM, Bleisch B, Voit A, et al. Survey of macrolide-resistant *Mycoplasma pneumoniae* in children with community-acquired pneumonia in Switzerland. *Swiss Med Wkly* 2014; **144**: w14041.
- 4 Hardegger D, Nadal D, Bossart W, Altwegg M, Dutly F. Rapid detection of *Mycoplasma pneumoniae* in clinical samples by real-time PCR. *J Microbiol Methods* 2000; **41**: 45-51.
- 5 Berger N, Muyltermans G, Dupont Y, Quoilin S. Assessing the sensitivity and representativeness of the Belgian Sentinel Network of Laboratories using test reimbursement data. *Arch Public Health* 2016; **74**: 29.
- 6 Ursi D, Dirven K, Loens K, Ieven M, Goossens H. Detection of *Mycoplasma pneumoniae* in respiratory samples by real-time PCR using an inhibition control. *J Microbiol Methods* 2003; **55**: 149-53.
- 7 Spuesens EB, Hoogenboezem T, Sluifster M, Hartwig NG, van Rossum AM, Vink C. Macrolide resistance determination and molecular typing of *Mycoplasma pneumoniae* by pyrosequencing. *J Microbiol Methods* 2010; **82**: 214-22.
- 8 Dumke R, Benitez AJ, Chalker V, et al. Multi-center evaluation of one commercial and 12 in-house real-time PCR assays for detection of *Mycoplasma pneumoniae*. *Diagn Microbiol Infect Dis* 2017; **88**: 111-4.

- 9 Rasmussen JN, Voldstedlund M, Andersen RL, et al. Increased incidence of *Mycoplasma pneumoniae* infections detected by laboratory-based surveillance in Denmark in 2010. *Euro Surveill* 2010; **15**: 19708.
- 10 Haapanen M, Renko M, Artama M, Kuitunen I. The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children - A nationwide register study in Finland. *EClinicalMedicine* 2021; **34**: 100807.
- 11 Kawai Y, Miyashita N, Kubo M, et al. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant *Mycoplasma pneumoniae* pneumonia in pediatric patients. *Antimicrob Agents Chemother* 2013; **57**: 2252-8.
- 12 Hung HM, Chuang CH, Chen YY, et al. Clonal spread of macrolide-resistant *Mycoplasma pneumoniae* sequence type-3 and type-17 with recombination on non-P1 adhesin among children in Taiwan. *Clin Microbiol Infect* 2021; **27**: 1169.e1-e6.
- 13 Wu TH, Wang NM, Liu FC, et al. Macrolide resistance, clinical features, and cytokine profiles in Taiwanese children with *Mycoplasma pneumoniae* infection. *Open Forum Infect Dis* 2021; **8**: ofab416.
- 14 Rodriguez N, Mondeja B, Sardinias R, Vega D, Dumke R. First detection and characterization of macrolide-resistant *Mycoplasma pneumoniae* strains in Cuba. *Int J Infect Dis* 2019; **80**: 115-7.